PMID- 26265235
OWN - NLM
STAT- MEDLINE
DCOM- 20160629
LR  - 20181202
IS  - 1744-8042 (Electronic)
IS  - 1462-2416 (Linking)
VI  - 16
IP  - 11
DP  - 2015
TI  - Rash in lapatinib-treated patients is not associated with human leukocyte antigen 
      polymorphisms.
PG  - 1227-9
LID - 10.2217/pgs.15.69 [doi]
AB  - Rash is a common side effect of lapatinib treatment. Since human leukocyte 
      antigen (HLA) alleles have been implicated in multiple drug-induced cutaneous 
      reactions, this study investigated the association of HLA alleles with 
      lapatinib-induced rash. 1191 participants from a large lapatinib monotherapy 
      trial underwent HLA genotyping, and allele carriage frequencies between rash 
      cases and controls were compared. This analysis had adequate power to detect an 
      association of common HLA alleles with rash, similar to those reported 
      previously. No HLA alleles were significantly associated with lapatinib-induced 
      rash, including the previously identified lapatinib hepatotoxicity biomarker 
      HLA-DRB1*07:01 (p = 0.87). The present study is consistent with the view that 
      lapatinib-induced rash is not the consequence of HLA-restricted, immune-mediated 
      mechanisms.
FAU - Parham, Laura R
AU  - Parham LR
AD  - PAREXEL International, Research Triangle Park, NC, USA (previously employed by 
      GlaxoSmithKline; work performed on this publication done while employed by 
      GlaxoSmithKline).
FAU - Briley, Linda P
AU  - Briley LP
AD  - PAREXEL International, Research Triangle Park, NC, USA (previously employed by 
      GlaxoSmithKline; work performed on this publication done while employed by 
      GlaxoSmithKline).
FAU - King, Karen S
AU  - King KS
AD  - PAREXEL International, Research Triangle Park, NC, USA (previously employed by 
      GlaxoSmithKline; work performed on this publication done while employed by 
      GlaxoSmithKline).
FAU - Byrne, Julie
AU  - Byrne J
AD  - Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA (previously employed 
      by GlaxoSmithKline; work performed on this publication done while employed by 
      GlaxoSmithKline).
FAU - Rappold, Erica
AU  - Rappold E
AD  - Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA (previously employed 
      by GlaxoSmithKline; work performed on this publication done while employed by 
      GlaxoSmithKline).
FAU - Goss, Paul E
AU  - Goss PE
AD  - Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
FAU - Spraggs, Colin F
AU  - Spraggs CF
AD  - GlaxoSmithKline Research & Development, Medicines Research Centre, Gunnels Wood 
      Road, Stevenage, Hertfordshire, SG1 2NY, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150812
PL  - England
TA  - Pharmacogenomics
JT  - Pharmacogenomics
JID - 100897350
RN  - 0 (Antineoplastic Agents)
RN  - 0 (HLA Antigens)
RN  - 0 (Quinazolines)
RN  - 0VUA21238F (Lapatinib)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Alleles
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - DNA/genetics
MH  - Drug Eruptions/*genetics/immunology
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - HLA Antigens/*genetics
MH  - Heterozygote
MH  - Humans
MH  - Lapatinib
MH  - Polymorphism, Genetic/genetics
MH  - Quinazolines/*adverse effects/therapeutic use
OTO - NOTNLM
OT  - HLA polymorphisms
OT  - lapatinib
OT  - rash
EDAT- 2015/08/13 06:00
MHDA- 2016/06/30 06:00
CRDT- 2015/08/13 06:00
PHST- 2015/08/13 06:00 [entrez]
PHST- 2015/08/13 06:00 [pubmed]
PHST- 2016/06/30 06:00 [medline]
AID - 10.2217/pgs.15.69 [doi]
PST - ppublish
SO  - Pharmacogenomics. 2015;16(11):1227-9. doi: 10.2217/pgs.15.69. Epub 2015 Aug 12.